New review highlights expanding potential of therapeutic DNA vaccines

A new review published in Genes & Diseases highlights the expanding potential of DNA-based vaccines as a flexible platform for preventing infectious diseases, treating cancer and strengthening preparedness for future disease outbreaks. The article charts the evolution of DNA vaccination from early concepts in the 1990s to increasingly sophisticated technologies with applications across infectious disease, oncology and precision medicine.

Unlike conventional vaccines that may use weakened or inactivated pathogens or protein components, DNA vaccines deliver genetic instructions encoding selected antigens. Once inside host cells, this DNA enables production of the antigen, which can then stimulate both humoral and cellular immune responses. The platform includes plasmid-based approaches as well as viral vector systems, each offering distinct advantages and challenges.

The COVID-19 pandemic accelerated interest in nucleic acid vaccination and demonstrated the value of vaccine platforms that can be rapidly adapted to emerging threats. The authorization of ZyCoV-D, the first plasmid DNA vaccine authorized for human use, represented an important milestone. DNA vaccine platforms may offer practical benefits including thermal stability, relatively low production costs, rapid design and scalability, characteristics that could be particularly valuable for global vaccination programs and pandemic preparedness.

The review also examines advances in vaccine delivery technologies, vector engineering and molecular adjuvants designed to strengthen immune responses. Viral vectors, including adenoviral systems, can facilitate efficient delivery of genetic material, while approaches such as electroporation and other specialized delivery methods may improve uptake of plasmid DNA.

Beyond infectious diseases, therapeutic DNA vaccines are attracting attention in areas such as cancer immunotherapy and chronic infections. Clinical development has included applications involving melanoma, prostate cancer, cervical cancer and glioblastoma, alongside infectious diseases such as hepatitis B, HIV and HPV-associated conditions.

Emerging technologies could further broaden the platform's capabilities. Artificial intelligence may support antigen and epitope identification, while synthetic biology can enable rapid redesign of vaccine constructs as pathogens evolve.

Important barriers remain, including relatively low immunogenicity in humans, inefficient delivery of some DNA constructs, manufacturing challenges for advanced viral vectors and limited regulatory approvals. Continued improvements in delivery, antigen design and immune stimulation will be essential.